@entity1652 revisited: its emerging role in the treatment of XXXX and early penile rehabilitation following @entity263 therapy.

@entity1 @entity323 @entity263 @entity101 @entity6 @entity1652 @entity545 @entity34882 @entity5501 @entity453 @entity546
INTRODUCTION: @entity1652 ( @entity1652 ) are becoming first-line therapies for the treatment of @entity323 and preservation (rehabilitation) of erectile function following treatment for @entity263 . Currently, there is limited efficacy of the use of phosphodiesterase type 5 inhibitors in elderly @entity1 , or @entity1 with moderate to severe @entity6 , @entity101 , and @entity453 . AIM: The article aims to study the role of @entity34882 in @entity1 following @entity263 therapy. RESULTS: Alternative therapies such as @entity34882 have emerged as one of the primary options for @entity1 refractory to oral therapy. @entity34882 has also been successfully used in combination treatment with oral therapy and penile injections. More recently, there has been interest in the use of @entity34882 in early intervention protocols to encourage corporeal rehabilitation and prevention of @entity5501 . This is evident by the preservation of @entity546 and girth that is seen with early use of the @entity34882 following radical prostatectomy. There are ongoing studies to help preserve @entity546 and girth with early use of @entity34882 following prostate brachytherapy and external beam radiation for @entity263 . Recently, there has also been interest in the use of @entity34882 to help maintain @entity546 following surgical correction of @entity545 and to increase penile size prior to implantation of the penile prosthesis. CONCLUSION: @entity1652 can be one of the options for penile rehabilitation after @entity263 therapy.
